RecruitingPHASE1, PHASE2NCT06970106
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy
Studying Autosomal dominant optic atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PYC Therapeutics
- Intervention
- PYC-001(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (3)
- Save Sight Institute - Sydney Eye Hospital, Sydney, New South Wales, Australia
- Cerulea Clinical Trials, East Melbourne, Australia
- Retina Specialists, Auckland, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06970106 on ClinicalTrials.govOther trials for Autosomal dominant optic atrophy
Additional recruiting or active studies for the same condition.